

ASX RELEASE

23 August 2021

ASX: NVU

Nanoveu Continues Global Expansion with Antiviral Face Masks

Highlights:

- **Nanoveu has received an order to supply over A\$125,000 of non-woven polypropylene fabric incorporating its antiviral technology**
- **The material will be used for the manufacture of protective face masks**
- **This is a trial size order with revenues expected to be A\$250,000 quarterly**
- **The masks will be manufactured in Thailand and is intended to be sold in multiple regions under various labels including Nanoveu's Nanoshield brand**
- **The non-woven fabric contains the same active antiviral compound as Nanoveu's Nanoshield films which have shown excellent efficacy against viruses and bacteria**
- **In addition to the antibacterial and antiviral properties, this material also reduces smells enabling continued use of face masks for approximately five days rather requiring disposal after a single use**

Nanoveu Limited (**ASX: NVU**) ("**Nanoveu**" or the "**Company**") is pleased to announce an expansion of its antiviral product applications with an order of A\$125,000 from its distributor for Thailand and Malaysia, Singapore Sanyo Trading Pte Ltd (*see ASX Announcement of 20 August 2020*), for a newly developed antiviral, non-woven polypropylene material which will be used to manufacture antiviral face masks.

The masks are interwoven with Nanoshield™ antiviral and antibacterial technology.

Nanoveu will sell these masks through its established distribution network under the Nanoshield™ brand.

This new antiviral polypropylene material opens opportunities for Nanoveu to pursue applications for its antiviral products in the personal protective equipment industry and may extend to additional applications such as disposable bedding and medical gowns in the medical sector.

Nanoveu's antiviral technology has been independently demonstrated to be a highly effective agent for the inactivation of viruses and bacteria. The technology has been proven to eliminate 99.99% of SARS-CoV-2 (COVID-19) and HCoV-299E, OC43, another coronavirus affecting humans in 30 minutes¹.

In addition to SARS-CoV-2 (COVID-19) and HCoV-299E, Nanoveu's antiviral technology has been independently demonstrated to be a highly effective agent for the inactivation of other

¹ See announcement of 28 July 2021

viruses. The technology has been proven to eliminate 99.99%² of OC43, another coronavirus affecting humans in 30 minutes. The antiviral protection has also been validated against other bacteria and viruses including E. coli, Influenza A (subtype H3N2), and coronavirus MHV-A59³. Additionally, testing simulating 12 months outdoor weather exposure has found Nanoveu’s film products retain their effectiveness against MS2 Bacteriophage, a single-strand RNA virus⁴.

Nanoshield technology has been tested extensively across the United States, Japan, Singapore, India, China, Europe and Dubai and has been recognised as a proven self-disinfectant material in a number of applications.

Should the current trial prove successful, Nanoveu is targeting recurring sales of this product, however, Nanoveu notes there is no guarantee of future sales.

A photo of the product is pictured in Figure 1.



Figure 1: Nanoshield™ Surgical mask packaging

Alfred Chong, Founder, Executive Director and CEO of Nanoveu commented:

“As an ASX-listed company we are delighted to continue our work within Australia providing successful solutions against viral diseases. The continued global support for the masks validates the superiority and efficacy of Nanoveu’s Nanoshield™. With reinstated lockdowns across

² See announcements of 5 and 25 May 2020

³ See announcement of 15 April 2020

⁴ See ASX announcement of 18 February 2021

Australia, businesses are in severe need of solutions to address the challenges of living with COVID-19 and we believe Nanoshield™ can aid Australian citizens and businesses in returning to normal working and living environments.

“Nanoshield’s™ status has been recognised as a globally significant product and from an international standpoint we believe there are a considerable number of countries that can be engaged, positively impacting patient health outcomes and assisting in fighting various strains of viruses.”

This announcement has been authorised for release by Nanoveau’s Executive Chairman and CEO.

- ENDS -

For further information, please contact:

Alfred Chong
Executive Chairman and CEO

t: +65 6557 0155
e: info@nanoveu.com

For media / investor enquiries, please contact:

Jane Morgan
Investor Relations

t: 0405 555 618
e: jm@janemorganmanagement.com.au

About Nanoveau Limited

We are technology innovators who specialize in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. <https://www.nanoveu.com/>

Nanoshield - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to a number of surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.

EyeFly3D - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.

Customskins - are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.

EyeFyx - currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.